Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement

Fineline Cube Jun 17, 2026
Company Deals

Servier Group Partners with n-Lorem Foundation to Develop ASO Therapies for Rare Neurodevelopmental Disorders

Fineline Cube Jun 17, 2026
Company Deals

Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors

Fineline Cube Jun 17, 2026
Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Fineline Cube Jun 16, 2026
Company Deals

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

Fineline Cube Jun 16, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial

Fineline Cube Jun 17, 2026
Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders

Fineline Cube Jun 17, 2026
Company Drug

Kelun Pharma’s Generic Jardiance Gains New Indication in China

Fineline Cube Feb 17, 2023

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has obtained another indication approval in China...

Policy / Regulatory

Hangzhou Singclean Stripped of VBP Status for Artificial Lenses

Fineline Cube Feb 17, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has revealed that Hangzhou Singclean Medical Products Co., Ltd...

Company Deals R&D

Topgen Biopharm Partners with Fudan University for Breast Cancer Gene Detection

Fineline Cube Feb 17, 2023

Zhejiang-based tumor precision medicine specialist Topgen Biopharm Co., Ltd has entered into a strategic partnership...

Company Deals Digital

By-Health Partners with Meituan’s Drug Purchase APP for New Retail Expansion

Fineline Cube Feb 17, 2023

China-based By-Health Co., Ltd. (SHE: 300146) has entered into a strategic partnership with Meituan’s drug...

Company Deals

Kangtai Biological Partners with Pakistani Firm for Pneumonia Vaccine Expansion

Fineline Cube Feb 17, 2023

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced a strategic partnership with...

Company Deals Medical Device

Shanghai-Based REMD Raises Series A+ Funding for Electroporation Device Expansion

Fineline Cube Feb 17, 2023

Shanghai-based REMD, a leading manufacturer of irreversible electroporation devices, has reportedly raised over RMB 100...

Company Drug

NMPA Approves Keverprazan for Duodenal Ulcers and Reflux Esophagitis

Fineline Cube Feb 17, 2023

The National Medical Products Administration (NMPA) has granted approval to Jiangsu Carephar Pharmaceutical Co., Ltd’s...

Company

Organon Reports Q4 and Full-Year 2022 Financials with Revenue Declines

Fineline Cube Feb 17, 2023

US-based Organon Inc. (NYSE: OGN) has released its Q4 and full-year 2022 financial results. Global...

Company Deals Digital R&D

WinHealth Pharma Taps Baidu’s ERNIE Bot for Rare Disease Services

Fineline Cube Feb 16, 2023

China-based Hong Kong WinHealth Pharma Group Ltd’s Bo’Ao Winhealth Rare Disease Medical Center has accessed...

Company

Eppendorf to Start Construction on New Shanghai Production Site

Fineline Cube Feb 16, 2023

Germany-based life sciences service provider Eppendorf is set to begin work on a new production...

Company Deals

InnoCare Regains Rights to Orelabrutinib as Biogen Terminates Licensing Agreement

Fineline Cube Feb 16, 2023

Beijing InnoCare Pharma Tech Co., (HKG: 9969), a China-based biotech focusing on cancer and autoimmune...

Company Drug

AIM Vaccine Gains Approvals for COVID-19 mRNA Vaccine Trials in Pakistan

Fineline Cube Feb 16, 2023

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving separate approvals in Pakistan to...

Company Drug

Innovent Biologics Initiates Phase III CLEAR Study for Picankibart in Psoriasis

Fineline Cube Feb 16, 2023

China-based Innovent Biologics (HKG: 1801) has announced the first subject dosing in the Phase III...

Company Drug

Frontera Therapeutics Initiates FT-002 Clinical Study for X-Linked Retinitis Pigmentosa

Fineline Cube Feb 16, 2023

Sino-US gene therapy specialist Frontera Therapeutics has announced the first patient dosing in a clinical...

Company Drug

Kanghong’s KH617 Receives Orphan Drug Designation for Glioblastoma

Fineline Cube Feb 16, 2023

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving an Orphan Drug...

Company Drug

Luye Pharma’s BA2101 Begins Phase I Clinical Trial for Allergic Diseases

Fineline Cube Feb 16, 2023

China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase...

Company Drug

CDE Accepts Clinical Trial Filing for Ranok’s First-in-Class BRD4 Degradation Drug RNK05047

Fineline Cube Feb 16, 2023

The Center for Drug Evaluation (CDE) website indicates that a clinical trial filing for RNK05047,...

Company Drug

Junshi Biosciences and Coherus Report Positive JUPITER-02 Trial Results for NPC Treatment

Fineline Cube Feb 16, 2023

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) and its US partner Coherus BioSciences...

Company Deals

Eyenovia Partners with Formosa Pharmaceuticals for Ophthalmic Therapeutics

Fineline Cube Feb 16, 2023

US-based Eyenovia Inc., (NASDAQ: EYEN) has announced a strategic development and collaboration agreement with Taiwan-based...

Company Deals

Brii Biosciences Publishes Positive Phase II Results for HBV Treatment

Fineline Cube Feb 15, 2023

China’s Brii Biosciences (HKG: 2137) has announced the publication of interim results from a Phase...

Posts pagination

1 … 581 582 583 … 685

Recent updates

  • Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial
  • Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders
  • Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy
  • WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement
  • Hengrui Pharmaceuticals Receives NMPA Clinical Approvals for Two Novel Anti-Tumor Candidates SHR-6914 and HRS-7525, Addressing Unmet Needs in Prostate Cancer and Solid Tumors
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial

Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders

Company Drug

Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy

Company Deals

WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.